University of Chieti, Department of Paediatrics, Ospedale policlinico, Via dei vestini 5, 66100 Chieti, Italy.
Expert Opin Pharmacother. 2012 Oct;13(14):2065-72. doi: 10.1517/14656566.2012.713347. Epub 2012 Aug 8.
Lacosamide is a novel antiepileptic drug licensed in the US and Europe as adjunctive therapy for partial-onset seizures in adults. The efficacy, safety, tolerability and favorable pharmacokinetic profile in the adult population suggest that lacosamide could be of benefit for patients with partial-onset seizures.
This paper reviews the available evidence and most recent data concerning the efficacy, safety, tolerability and pharmacokinetics of lacosamide in adults, as well as in the pediatric population.
Lacosamide is one of the newest drugs of the antiepileptic armamentarium, and it is expected to compete directly with compounds that are currently used for adjunctive therapy in adults with refractory partial epilepsy. The intravenous formulation may be used for replacement therapy in patients temporarily unable to take oral medication. An apparent lack of sedative or cognitive effects might render this drug preferable in patients with mental insufficiency and/or epileptic encephalopathy.
拉科酰胺是一种新型抗癫痫药物，已在美国和欧洲获得批准，作为成人部分发作性癫痫的辅助治疗药物。其在成年人群中的疗效、安全性、耐受性和良好的药代动力学特征表明，拉科酰胺可能对部分发作性癫痫患者有益。
本文综述了拉科酰胺在成人和儿科人群中的疗效、安全性、耐受性和药代动力学的现有证据和最新数据。
拉科酰胺是抗癫痫药物的最新药物之一，预计将与目前用于治疗耐药性部分性癫痫的辅助治疗药物直接竞争。静脉制剂可用于暂时无法口服药物的患者的替代治疗。该药显然没有镇静或认知作用，这可能使该药在精神功能不全和/或癫痫性脑病患者中更具优势。
